XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · IEX Real-Time Price · USD
2.440
0.00 (0.00%)
At close: Apr 19, 2024, 3:14 PM
2.330
-0.110 (-4.51%)
After-hours: Apr 19, 2024, 4:18 PM EDT
Company Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd.
| Country | Israel |
| Founded | 1993 |
| IPO Date | Sep 1, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Shlomo Spokone Shalev |
Contact Details
Address: 120 Broadway, 32nd Floor New York, New York 10271 United States | |
| Phone | 2122383128 |
| Website | xtlbio.com |
Stock Details
| Ticker Symbol | XTLB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001696804 |
| CUSIP Number | 98386D307 |
| ISIN Number | US98386D3070 |
Key Executives
| Name | Position |
|---|---|
| Shlomo Spokone Shalev | Chief Executive Officer and Director |
| Itay Weinstein | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 8, 2017 | 424B3 | Prospectus |